Literature DB >> 26823021

T2* relaxation time in the detection and assessment of aggressiveness of peripheral zone cancer in comparison with diffusion-weighted imaging.

L-M Wu1, B Zhou1, Q Lu1, S-T Suo1, Q Liu2, J Hu3, E M Haccke3, X-X Chen1, J-R Xu4.   

Abstract

AIM: To investigate the feasibility of T2* relaxation time for distinguishing benign from malignant regions, as well as tumour aggressiveness, within the peripheral zone (PZ) of the prostate in comparison with diffusion-weighted imaging (DWI).
MATERIALS AND METHODS: Fifty-eight patients with prostate cancer underwent 3 T magnetic resonance imaging using multi-echo T2* and DWI (maximum b-value, 2000 s/mm(2)). Parametric maps were obtained for apparent diffusion coefficient (ADC) and T2* values. Two radiologists reviewed these maps and measured ADC and T2* values in sextants positive for cancer at biopsy. Data were analysed using mixed-model analysis of variance and receiver operating characteristic curves.
RESULTS: Ninety-three sextants exhibited a Gleason score of 6; 59 exhibited a Gleason score of 7 or 8. The T2* value was significantly lower in cancerous sextants than in the benign PZ (48.69+0.60 versus 74.14+0.56, p<0.001), as well as in cancerous sextants with higher rather than lower Gleason scores (43.18+0.89 versus 52.18+0.55, p<0.001). The T2* value showed significantly greater specificity for differentiating cancerous sextants from benign PZ than ADC (93.1% versus 89.7%, p<0.001), with equal sensitivity (82.8% versus 81%, p>0.05). The T2* value exhibited significantly greater sensitivity and specificity for differentiating sextants with low- and high-grade cancer than ADC (79.6% versus 64.5% and 81.4% versus 72.9%, respectively; p<0.05). The T2* value had a significantly greater area under the receiver operating characteristic curve for differentiating sextants with low- and high-grade cancer than ADC (0.77 versus 0.71, p<0.01).
CONCLUSION: Preliminary findings suggest that the T2* relaxation time has increased diagnostic value compared with DWI in prostate PZ cancer assessment.
Copyright © 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26823021     DOI: 10.1016/j.crad.2015.12.012

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  4 in total

1.  A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).

Authors:  Sonia Gaur; Stephanie Harmon; Rajan T Gupta; Daniel J Margolis; Nathan Lay; Sherif Mehralivand; Maria J Merino; Bradford J Wood; Peter A Pinto; Joanna H Shih; Peter L Choyke; Baris Turkbey
Journal:  Acad Radiol       Date:  2018-04-25       Impact factor: 3.173

2.  Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer.

Authors:  Alice C Yu; Chaitra Badve; Lee E Ponsky; Shivani Pahwa; Sara Dastmalchian; Matthew Rogers; Yun Jiang; Seunghee Margevicius; Mark Schluchter; William Tabayoyong; Robert Abouassaly; Debra McGivney; Mark A Griswold; Vikas Gulani
Journal:  Radiology       Date:  2017-02-10       Impact factor: 11.105

3.  Creatine CEST MRI for Differentiating Gliomas with Different Degrees of Aggressiveness.

Authors:  Kejia Cai; Rong-Wen Tain; Xiaohong Joe Zhou; Frederick C Damen; Alessandro M Scotti; Hari Hariharan; Harish Poptani; Ravinder Reddy
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

4.  Optimized b-value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging.

Authors:  Sarah L Hurrell; Sean D McGarry; Amy Kaczmarowski; Kenneth A Iczkowski; Kenneth Jacobsohn; Mark D Hohenwalter; William A Hall; William A See; Anjishnu Banerjee; David K Charles; Marja T Nevalainen; Alexander C Mackinnon; Peter S LaViolette
Journal:  J Med Imaging (Bellingham)       Date:  2017-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.